Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Dornase alfa vs placebo or no dornase alfa treatment

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).

1 finding from 1 review

Dornase alfa vs placebo or no dornase alfa treatment

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).

2 findings from 1 review

Dornase alfa vs placebo or no dornase alfa treatment

Exacerbations · adults and children with cystic fibrosis

Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Mortality Mortality at latest · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Early systemic postnatal corticosteroids vs placebo or no treatment

Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants

Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).

1 finding from 1 review